meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population 5
es-BC - TNBC - NA - PDL1 positive 1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1) 1
mBC - TNBC - L1 - all population 7
mBC - TNBC - L1 - PDL1 positive 4
mBC-Triple negative (TNBC) - 2nd Line (L2) 3
mBC - TNBC - L2 - all population 2
mBC - TNBC - L2 - PDL1 positive 2

antibody–drug conjugate
sacituzumab govitecan
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
talazoparib

versus all
vs chemotherapy
vs Standard of Care (SoC)

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -